8-K: Regen Biopharma Settles Lawsuit, Changes Auditors

Regen Biopharma Inc. announced a settlement agreement resolving a lawsuit for $398,740 and the appointment of a new independent registered public accounting firm.

Summary

• Regen Biopharma, Inc. has entered into a Settlement and Mutual Release Agreement to resolve a complaint filed by Trillium Partners, LP, who acquired rights to $398,740 in claims against the company.
• The settlement requires Regen Biopharma to issue shares of its Common Stock or Series A Preferred Stock to the plaintiff, with the value of the shares sufficient to generate 65% of the net proceeds from their sale, equaling the $398,740 claim amount.
• The Superior Court of California approved the issuance of these settlement shares on July 10, 2026, after a fairness hearing.
• The company also announced changes to its independent registered public accounting firm. BCRG Group was dismissed, and Simon & Edward LLP was appointed as the new auditor, effective July 13, 2026.
• BCRG Group's audit reports for fiscal years 2024 and 2025 included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Regen Biopharma also filed a Certificate of Designations with the Nevada Secretary of State, establishing a new Series N Preferred Stock with significant voting rights (75,000,000 votes per share).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the dilution from settling a lawsuit with stock and the significant, potentially disruptive voting power of the newly created preferred stock, despite the resolution of legal matters.

Positives

• Resolution of a significant legal claim, removing uncertainty and potential future liabilities.
• Court approval of the settlement, indicating a fair resolution process.
• Appointment of a new accounting firm, which may bring fresh perspectives or address prior concerns.
• Establishment of a new preferred stock series with substantial voting power, potentially for strategic purposes.

Negatives

• The company must issue stock to settle a $398,740 claim, which will dilute existing shareholders.
• The settlement requires 65% of the net proceeds from the sale of settlement shares to equal the claim amount, implying potential difficulties in achieving the full value.
• The previous auditor's reports highlighted substantial doubt about the company's ability to continue as a going concern.
• The new Series N Preferred Stock has extremely high voting power, which could significantly alter corporate control and governance.

Risks

• The issuance of settlement shares could lead to significant dilution for existing common stockholders.
• The substantial voting power of the Series N Preferred Stock could be used to exert control over the company, potentially against the interests of common shareholders.
• The company's ability to continue as a going concern, as previously noted by its former auditor, remains a significant risk.
• The terms of the settlement require 65% of net proceeds from share sales to cover the claim, which may not be achievable depending on market conditions for the stock.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, the settlement of litigation and the change in auditors are significant events that will impact future financial reporting and operational focus.

Management Comments

• The company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
• The Audit Committee of the Company's Board of Directors simultaneously dismissed BCRG as the Company's independent registered public accounting firm and approved the appointment of S&E as the Company's new independent registered public accounting firm.

Industry Context

StockSavvy.ai notes that auditor changes and litigation settlements are common events for small-cap companies, particularly those facing financial scrutiny. The creation of a preferred stock with such significant voting power is an unusual move that warrants close monitoring.

Corporate Governance

Legal Proceedings

• Settlement of a lawsuit filed by Trillium Partners, LP, for $398,740 in damages, attorneys fees, and costs.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of settlement shares; potential shift in control due to Series N Preferred Stock's voting power.
• Creditors: Resolution of a claim against the company may improve its financial standing.
• Management: Navigating the implications of the new preferred stock series and auditor change.

Next Steps

• Issuance of Settlement Shares to Trillium Partners, LP.
• Commencement of services by Simon & Edward LLP as the new independent registered public accounting firm.
• Potential future actions related to the Series N Preferred Stock and its voting power.

Key Dates

Recommendation

The filing resolves a significant legal uncertainty and addresses auditor changes, which are positive steps. However, the substantial dilution from the settlement and the creation of a highly potent preferred stock series introduce significant risks and potential governance concerns that warrant a cautious 'hold' stance until further clarity on the use and impact of the Series N Preferred Stock emerges.

Keywords

Regen Biopharma, 8-K Filing, Settlement Agreement, Trillium Partners, Legal Proceedings, Auditor Change, Preferred Stock, Going Concern